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ABSTRACT
Background: Interleukin (IL)-13 induces goblet cell metaplasia and plays an important role in mucus hyper-
secretion in asthma. We previously reported that IL-13 induced goblet cell differentiation along with less ciliated
cell differentiation in guinea pig tracheal epithelial cells in vitro. In this study, we asked whether elimination of
IL-13 could reverse the established goblet cell metaplasia into ciliated epithelia.
Methods: Primary epithelial cells from guinea pig tracheas were cultured at an air-liquid interface with the me-
dium containing human recombinant IL-13 for 14 days, and continuously cultured with IL-13-eliminated me-
dium, or cultured under the condition of neutralization of IL-13 with anti IL-13 antibody.
Results: 2 days after elimination of IL-13, the periodic acid-Schiff-positive area as well as MUC5AC protein
level rapidly decreased. After 4 days, the number of goblet cells dramatically decreased, while that of ciliated
cells inversely increased. The total number of epithelial cells did not change, and 5-bromo-2’-deoxyuridine up-
take decreased after IL-13 elimination. Transitional cells with cilia and secretory granules increased after IL-13
elimination. Similarly, the neutralization of IL-13 with anti-IL-13 antibody for 5 days reversed the goblet cell
metaplasia into ciliated epithelia, and transitional cells also increased.
Conclusions: Elimination of IL-13 reverses goblet cell metaplasia into ciliated epithelia in vitro, and transition
of goblet cells to other phenotypes, especially ciliated cells, may be involved in this phenomenon. IL-13 inhibi-
tion may be a therapeutic strategy of established goblet cell metaplasia in asthma.
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INTRODUCTION
Goblet cell metaplasia in airways has been estab-
lished as one of pathologic characteristics of asthma.1
Mucus overproduction due to goblet cell metaplasia
causes airway narrowing, loss in lung function and
occasionally asthmatic death.2 However, the specific
treatments for mucus overproduction are not cur-
rently available.
There is increasing evidence that Th2 cytokines,
especially IL-13, induce goblet cell metaplasia and
play an important role in mucin production. For ex-
ample, IL-13-transgenic mice and rats treated with in-
tratracheal instillation of IL-13 demonstrate marked
goblet cell metaplasia.3,4 We previously reported that
IL-13 induced marked goblet cell differentiation along
with inhibition of ciliated cell differentiation , when
primary airway epithelial cells from guinea pigs were
cultured at air-liquid interface under the condition of
the long-term exposure to IL-13.5 Atherton et al. simi-
larly reported that IL-13 increased goblet cell density
of cultured human bronchial epithelial cells.6 It is an
important strategy for the treatment of hypersecre-
tion in asthma to elucidate the mechanism of resolu-
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Fig. 1 The efects of elimination of IL-13 on goblet cel 
number (A) and ciliated cel number (B). Control (day 0, day 
10): the cels were cultured in the absence of IL-13 for 14 
days (day 0), and cultured in the absence of IL-13 for more 
10 days (day 10). IL-13 (day 0, day 10): the cels were cul-
tured in the presence of IL-13 for 14 days (day 0), and cul-
tured in the presence of IL-13 for more 10 days (day 10). 
Elimination of IL-13 (day 10): the cels were cultured in the 
presence of IL-13 for 14 days, and then cultured in the ab-
sence of IL-13 for 10 more days. n＝4. ＊＊P ＜ 0.01, ＊P ＜ 
0.05, IL-13 vs. other groups. †P ＜ 0.05 vs. IL-13 on day 10.
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tion of goblet cell metaplasia. Antigen cessation in-
duces resolution of goblet cell metaplasia along with
the decrease in IL-13 in the asthmatic animal model.7
Anti IL-13 antibody and soluble IL-13 receptor alpha 2
(sIL-13 Rα2)-IgG fusion protein reverse established
goblet cell metaplasia in animal asthma models . 8-10
However, the mechanism of resolution of goblet cell
metaplasia remains unclear . In this study with cul-
tured guinea pig tracheal epithelial cells , we have
demonstrated that elimination of IL-13 reverses estab-
lished goblet cell metaplasia into ciliated epithelia.
METHODS
Epithelial cells from guinea pig trachea were isolated
by digestion with 0.05% protease (type XIV, Sigma, St.
Louis, MO, USA) at 4℃ overnight. Cells were pel-
leted (200 g, 10 min) and suspended in a 50 : 50 mix-
ture of Dulbecco’s modified Eagle medium (DMEM)
and Ham’s F12 medium (GIBCO, Grand Island, NY,
USA) containing 5% fetal calf serum. Viability was
−90% as assessed by trypan blue exclusion . Cells
were plated at 2.5 × 105 cells per cm2 onto polycar-
bonate inserts of 12 mm diameter, 0.4-μm pore size,
and 10-μm thickness (Costar Transwell, Cambridge,
MA, USA), which had been coated with human pla-
cental collagen (type XVI, Sigma). From the first day
after plating, cells were cultured with a serum-free,
hormonally defined medium containing insulin (10
μgml, Sigma), transferrin (5 μgml, Sigma), triiodo-
thyronine (20 ngml, Sigma), epithelial cell growth
factor (EGF) (25 ngml, Sigma), all-trans retinoic
acid (5 × 10−8 M, Sigma) and endothelial cell growth
supplement (7.5 μgml, Sigma). After achieving con-
fluence, the apical medium was removed, and cells
were fed from only the basolateral side with 1 ml of
medium containing human recombinant IL-13 ( 10
ngml, Biosource International, Camarillo, CA, USA).
EGF was eliminated from the medium after conflu-
ence to avoid multilayer formation. Cells were cul-
tured at an air-liquid interface for 14 days with a me-
dium containing IL-13 and then continuously cultured
maximally for more than 10 days with an IL-13-
eliminated medium. In a separate experiment, mouse
monoclonal anti-human IL-13 antibody ( clone
32116.11, 1 μgml, 10 μgml, Sigma) or mouse IgG1
isotype (10 μgml, Sigma) was added for 5 days to
the epithelial cells that had been exposed to IL-13 (10
ngml) for 14 days. The date when elimination of IL-
13 or neutralization of IL-13 with anti-IL-13 antibody
had started was defined as day 0. Cells were main-
tained in an incubator under 21% O2 and 5% CO2 at 37
℃ , and culture media were changed once every 2
days.
For light and electron microscopic studies , the
cells on porous filters were fixed with glutaralde-
hydeosmium tetroxide , and embedded in epon .
Thick sections were stained with toluidine blue for
light microscopy. Thin sections (with a silver interfer-
ence color) were stained with lead citrate and uranyl
acetate for transmission electron microscopy (TEM).
For cell analysis, the total cell numbers were deter-
mined by counting epithelial cell nuclei over 1 mm of
the filter in cross sections of cultures with an oil im-
mersion objective lens (×1000 magnification) by light
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Fig. 2 Light microscopic photographs of the cultured tracheal epithelial cels. Upper 
panel: The cels treated with IL-13 for 14 days (defined as day 0). Lower panel: IL-13-elimi-
nated cels on day 10. Goblet cels were replaced into ciliated cels on day 10 after elimina-
tion of IL-13. Toluidine blue stain. Objective magnification×40.
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Fig. 3 Time courses of goblet cel number (A), ciliated cel number (B), total cel 
number (C) and transitional cel number (D) after elimination of IL-13. Goblet cel 
number rapidly decreased on day 4, while ciliated cel number inversely increased. 
Total cel number was not significantly changed during observation. Transitional 
cel number increased after day 4. Results were obtained from three diferent 
experiments. ＊ P ＜ 0.05, ＊＊ P ＜ 0.01 vs. the number of each cel type on day 0. 
† † P ＜ 0.01 vs. the number of each cel type on day 2.
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microscopy. The epithelial cells were classified as fol-
lows. Ciliated cells contained ciliated borders. Goblet
cells contained secretory granules. Basal cells were
small, flattened cells located just above the filter but
not reaching the apical portion . Transitional cells
were defined as the cells that contained both ciliated
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Fig. 4 Time course of BrdU uptake in cultured tracheal 
epithelial cels after elimination of IL-13. Data are shown as 
percent uptake of the IL-13-treated cels on day 0. Control 
(day 0): the cels have been cultured in the absence of IL-13 
for 14 days. IL-13 (day 0, day 6): the cels have been cul-
tured in the presence of IL-13 for 14 days (day 0), and cul-
tured in the presence of IL-13 for more 6 days (day 6). 
Elimination of IL-13 (day 2, day 4, day 6): the cels have 
been cultured in the presence of IL-13 for 14 days, and then 
cultured in the absence of IL-13 for 2, 4, 6 days. n＝3―5. 
＊＊P＜0.01 and ＊P＜0.05 vs. IL-13-treated cels on day 
0. †P＜0.05 vs. IL-13-treated cels on day 6.
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borders and secretory granules. The rest of the cells
were defined as others.
For assessment of mucin-specific staining by light
microscopy , cross sections of the cell sheet were
stained with periodic acid-Schiff (PAS). By using a
semiautomatic imaging system (Win Roof, Mitani Co.
Fukui, Japan), PAS-positive area and the total epithe-
lial area were measured and the data were expressed
as the percentage of the total area stained by PAS.
MUC5AC protein was measured using ELISA as
described by Takeyama et al.11 Cell lysates were pre-
pared with phosphate buffered saline (PBS) at multi-
ple dilutions, and 50 μl of each sample was incubated
with bicarbonate-carbonate buffer (50 μl) at 40℃ in
96-well plate (Nunc), until dry. Plates were washed
three times with PBS and then incubated with 50 μl of
mouse monoclonal MUC5AC antibody (clone 45 M1,
1 : 100, New Markers, Fremont, CA, USA), which
was diluted with PBS containing 0.05% Tween 20
(Sigma). After 1 hour, the wells were washed three
times with PBS , and 100 μl of horseradish
peroxidase-goat anti-mouse IgG conjugate (1 : 10,000,
Sigma) was added. After 1 hour, plates were washed
three times with PBS, color was developed with 3,3’,
5,5’-tetramethylbenzidine (TMB) peroxidase solution
(Kirkegaard & Perry Laboratories , Gaithersburg ,
MD, USA) and stopped with 1 M H2SO4. Absorbance
was read at 450 nm.
Cell proliferation was assessed by a commercial
ELISA kit (Roche Diagnostics GmbH, Mannheim,
Germany), based on the measurement of 5-bromo-2’-
deoxyuridine (BrdU) incorporation during DNA syn-
thesis in proliferating cells. Epithelial cells were incu-
bated with the diluted BrdU added to the basolateral
side prior to 24 hours. Then, the cells were washed
well with DMEMHam F12 medium and dried with a
hair-dryer for about 5 minutes, and stored at 0℃ for
maximal 6 days. The cells were fixed and incubated
with anti-BrdU-antibody conjugated with peroxidase
for 90 minutes. After the antibody was removed, color
was developed with TMB peroxidase solution and
stopped with 1 M H2SO4. Absorbance was read at 450
nm.
STATISTICS
All data are expressed as means ± SEM. One-way
ANOVA was used to determine statistically signifi-
cant differences between groups. Scheffe’s F test was
used to correct for multiple comparisons when statis-
tical significances were identified in the ANOVA. A
probability of <0.05 for the null hypothesis was ac-
cepted as indicating a statistically significant differ-
ence.
RESULTS
The cells treated with IL-13 (10 ngml) for 14 days
(defined as day 0) consisted of a large number of ma-
ture goblet cells with a small number of ciliated cells
(Figs. 1, 2). Non-treated, control cells on day 0 mainly
consisted of ciliated cells, whereas goblet cells were
rarely found (Fig. 1). On day 10 after elimination of
IL-13, most of the established goblet cells were re-
placed by ciliated cells (Figs. 1, 2). In contrast, the
number of each cell type was not changed on day 10
in IL-13-treated cells and the non-treated, control cells
(Fig. 1). The time course of each cell number after
elimination of IL-13 is shown in Figure 3 . Goblet cell
number rapidly decreased on day 4, while ciliated cell
number inversely increased (Figs. 3A, 3B). The total
number of the cells did not significantly change after
elimination of IL-13 (Fig. 3C). In a cell proliferation
assay, BrdU uptake of IL-13-treated cells on day 0 was
higher than that of non-treated, control cells on day 0
(Fig . 4). After IL-13 elimination , BrdU uptake de-
creased with time, and BrdU uptake of IL-13 elimi-
nated cells on day 4 and on day 6 were significantly
lower than that of IL-13-treated cells on day 0. BrdU
uptake of IL-13-treated cells on day 6 was the same
level as that on day 0, suggesting that BrdU uptake
level was not changed in IL-13-treated cells for 6 days.
Thus, BrdU uptake of IL-13-eliminated cells on day 6
was significantly lower than that of IL-13-treated cells
on day 6 (Fig. 4).
Prior to the decrease of goblet cell number, the sig-
nificant decrease in the PAS-positive area and
MUC5AC protein level of cell lysates already oc-
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Fig. 5 The time course of PAS-positive areas (A) and MUC5AC levels (B) of the cultured tracheal 
epithelial cels after elimination of IL-13. PAS-positive areas and MUC5AC levels significantly decreased 
after day 2. n＝4. ＊＊P＜0.01 vs. the values on day 0.
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curred on day 2 (Figs . 5A, 5B). In electron mi-
crographs , the secretory granules on day 2 were
smaller in size and number, and more electrodense
than those on day 0 (Figs. 6A, 6B). Degranulation
was rarely found. MUC5AC protein levels in the lav-
age fluid from the apical side on day 1―2 were not in-
creased compared with those on day 0 ( data not
shown). Interestingly , transitional cells with ciliary
borders and electro-dense secretory granules are fre-
quently observed after day 4, and the number was
significantly increased after day 4 (Figs. 3D, 6C).
To confirm the reversal from goblet cell metaplasia
to ciliated epithelia, we further studied the effect of
the neutralization of IL-13 with anti IL-13 antibody on
the established goblet cell metaplasia . Treatment
with anti IL-13 antibody (1 μgml, 10 μgml), but not
with control IgG1 isotype (10 μgml) for 5 days de-
creased the goblet cell number and increased the cili-
ated cell number (Figs. 7A, 7B). Total cell number
did not change (Fig. 7C). Transitional cells with cili-
ary borders and electro-dense secretory granules in-
creased under the condition of anti-IL-13 antibody
treatment (Figs. 6D, 7D).
DISCUSSION
In this study, we demonstrated that elimination of IL-
13 reversed established goblet cell metaplasia into
ciliated epithelia in vitro. We also demonstrated that
total cell number did not significantly change for 6
days after elimination of IL-13 without the increase in
cell proliferation, and the transitional cells with both
ciliary borders and secretory granules were in-
creased. These results suggest that newly appeared
ciliated cells are derived from transition of other
types of cells, especially goblet cells rather than cell
proliferation de novo. Furthermore, neutralization of
IL-13 with anti-IL-13 antibody for 5 days decreased
the number of goblet cells and increased that of cili-
ated cells, and transitional cells were frequently ob-
served. This may provide therapeutic evidence that
inhibition of IL-13 such as anti-IL-13 antibody directly
affects epithelial cells and resolves established goblet
cell metaplasia. Although the airway epithelial cells
are classically known to show plasticity,12 the transi-
tion of goblet cells to ciliated cells remains uncertain.
Interestingly, You et al. have recently reported that
transition of ciliated cells to goblet cells is induced by
IL-13 at air-liquid interface culture of murine tracheal
epithelial cells.13 Thus, our findings and their results
suggest that IL-13 is a key cytokine to transform cell
phenotype of airway epithelium. Yoshisue et al. have
reported that IL-13 inhibits ciliated cell-associated
genes and inhibits ciliogenesis, whereas IL-13 stimu-
lates MUC genes and induces goblet cell metapla-
sia.14 Therefore, further studies are needed to eluci-
date that elimination of IL-13 restores expression of
ciliated cell-associated genes and downregulates ex-
pression of MUC genes.
It is widely accepted that IL-13 is a central mediator
in asthma, and strongly associated with airway re-
modeling.3,15 IL-13 directly transforms human lung fi-
broblasts into myofibroblasts , 16 and changes physi-
ological responses to β-adrenergic agonists in human
airway smooth muscles.17 Our data as well as others
show that IL-13 interferes with ciliogenesis . 5,6,14,18
Therefore, IL-13 is an important cytokine for inducing
transformation in resident cells in the airway, which
also results in airway remodeling.
Our in vitro study may support several experi-
ments done in vivo. For example, the resolution of
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Fig. 6 Transmission electron microscopic photographs of the cultured tracheal 
epithelial cels. A: The cels on day 0. B: The cels on day 2. Secretory granules of 
the cels on day 2 are smaler and more electrodense than those on day 0. C: The 
transitional cel on day 4 after IL-13 elimination that possesses both cilia and se-
cretory granules. D: The transitional cel under the condition of neutralization of IL-
13 with anti-IL-13 antibody (10 μg/ml) for 5 days. Bar ＝1 μm.
A） B）
C） D）
goblet cell metaplasia after antigen cessation is ob-
served along with the decrease in IL-13 in allergic
asthmatic models.7 Anti-IL-13 antibody or sIL-13Rα2
instillation into the trachea recovers from established
goblet cell metaplasia.8-10 Therefore, IL-13 elimination
or inhibition may be a useful strategy for resolution of
established goblet cell metaplasia in asthma.
As shown in Figure 5, decreases in MUC5AC pro-
tein levels and PAS-stained areas preceded a de-
crease in the number of goblet cells. In fact, small,
sparse and electron-dense secretory granules were
concordant with these biochemical changes. Thus,
these data suggest that continuous stimulation with
IL-13 is needed to maintain MUC5AC synthesis and
secretory granules . An excessive mucin secretion
could explain the decrease in MUC5AC protein and
PAS-positive areas after IL-13 elimination. However,
this possibility is unlikely because morphological
findings did not show degranulation, and MUC5AC
levels in the supernatant during early phase (day 1―2)
did not increase.
Mucus overproduction due to goblet cell metapla-
sia causes airway narrowing, loss in lung function and
occasionally asthmatic death.2 Specific treatments for
mucus overproduction are not currently available .
Our study demonstrated the possibility of transition
of goblet cells to other cell types, especially ciliated
cells in vitro. If transition to ciliated cells is shown in
animal models, this may provide a new concept for
the treatment of established goblet cell metaplasia.
In conclusion, elimination of IL-13 reversed estab-
lished goblet cell metaplasia into ciliated epithelia in
airway epithelial cell culture. Transition may be in-
volved in this phenomenon. IL-13 inhibition may be a
therapeutic strategy of established goblet cell meta-
plasia in asthma.
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Fig. 7 The efects of anti-IL-13 antibody on goblet cel number (A), ciliated cel 
number (B), total cel number (C) and transitional cel number (D). Anti-IL-13 anti-
body (Ab 1 μg/ml, 10 μg/ml) or IgG1 isotype (10 μg/ml) was added for 5 days with 
IL-13 (10 ng/ml) to the epithelial cels that had been cultured with medium contain-
ing IL-13 for 14 days. Al groups are the cels on day 5. n＝4. ＊＊P ＜ 0.01, ＊P＜
0.05 vs. non-Ab-treated cels. † †P ＜ 0.01, †P＜ 0.05 vs. IgG1 isotype-treated 
cels.
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